Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088331 · ClinicalTrials.gov registry record
Artificial Urinary Sphincter Clinical Outcomes
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 145
- Enrollment target
NCT04088331: Completed study, sponsored by Boston Scientific Corporation.
NCT04088331 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 145 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04088331 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 145 participants
- Enrollment target
Study Summary
To evaluate the AMS 800 Artificial Urinary Sphincter (AUS) in men with primary stress urinary incontinence as measured by pad weight tests.
Primary Outcome
Number of subjects achieving 50% reduction or greater in baseline urinary incontinence as measured by 24-hour pad weight test at 12 months post device activation
Interventions
- DEVICE AMS 800 Artificial Urinary Sphincter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2019-10-14 |
| Est. Completion | 2024-05-13 |
What the finished NCT04088331 record still lists
NCT04088331 is an observational study that tracks outcomes without assigning an intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which AMS 800 Artificial Urinary Sphincter is the first listed.
NCT04088331 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04088331 about?
NCT04088331 is a clinical study titled "Artificial Urinary Sphincter Clinical Outcomes". To evaluate the AMS 800 Artificial Urinary Sphincter (AUS) in men with primary stress urinary incontinence as measured by pad weight tests.
What is the current status of trial NCT04088331?
This trial is currently completed. The enrollment target is 145 participants. The study started on 2019-10-14. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT04088331?
The interventions under investigation include: AMS 800 Artificial Urinary Sphincter (DEVICE).
Who is sponsoring clinical trial NCT04088331?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02688959 · 145 participants · NA
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
- NCT03586609 · 145 participants · Phase 2
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
- NCT03767595 · 145 participants · NA
ProACT Post-Approval Study
- NCT03808337 · 145 participants · Phase 2
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI